ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Atossa Therapeutics Inc

Atossa Therapeutics Inc (ATOS)

1.47
-0.01
(-0.68%)
Closed July 24 4:00PM
1.48
0.01
(0.68%)
After Hours: 7:33PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.48
Bid
1.46
Ask
1.50
Volume
824,881
1.44 Day's Range 1.50
0.62 52 Week Range 2.31
Market Cap
Previous Close
1.48
Open
1.48
Last Trade Time
Financial Volume
$ 1,216,279
VWAP
1.4745
Average Volume (3m)
1,059,677
Shares Outstanding
125,757,416
Dividend Yield
-
PE Ratio
-6.14
Earnings Per Share (EPS)
-0.24
Revenue
-
Net Profit
-30.09M

About Atossa Therapeutics Inc

Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other brea... Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in us. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Atossa Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ATOS. The last closing price for Atossa Therapeutics was $1.48. Over the last year, Atossa Therapeutics shares have traded in a share price range of $ 0.62 to $ 2.31.

Atossa Therapeutics currently has 125,757,416 shares outstanding. The market capitalization of Atossa Therapeutics is $186.12 million. Atossa Therapeutics has a price to earnings ratio (PE ratio) of -6.14.

ATOS Latest News

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the...

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief...

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

SEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate...

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index...

Atossa to Present at the Sidoti Small-Cap Investor Conference

SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor...

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.074.964539007091.411.51.319951521.40357044CS
40.4138.31775700931.071.51.0211192051.23319346CS
12-0.05-3.267973856211.531.811.0210596771.37484586CS
260.658580.15824710890.82152.310.774413510921.50433328CS
520.3530.97345132741.132.310.628787301.34665426CS
156-2.57-63.45679012354.054.570.516281042.12209099CS
260-0.57-27.80487804882.059.80.535093523.1828985CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
 20.10
(839.25%)
128.82k
RGCRegencell Bioscience Holdings Ltd
$ 15.15
(349.55%)
1.34M
ATPCAgape ATP Corporation
$ 0.2262
(58.18%)
107.32M
SLRXSalarius Pharmaceuticals Inc
$ 2.34
(51.95%)
60.04M
GSUNGolden Sun Health Technology Group Ltd
$ 7.46
(45.42%)
590.09k
FLYEFly E Group Inc
$ 1.1601
(-81.82%)
25.44M
RNAZTransCode Therapeutics Inc
$ 0.3035
(-61.70%)
9.78M
JAGXJaguar Health Inc
$ 1.755
(-58.90%)
15.47M
MIRAMIRA Pharmaceuticals Inc
$ 2.55
(-49.10%)
25.64M
IVPInspire Veterinary Partners Inc
$ 5.19
(-43.83%)
1.67M
SLNASelina Hospitality PLC
$ 0.026
(-29.73%)
220.33M
SPWRSunPower Corporation
$ 0.9514
(32.91%)
186.76M
NVDANVIDIA Corporation
$ 122.59
(-0.77%)
173.91M
ADILAdial Pharmaceuticals Inc
$ 1.3422
(26.62%)
160.04M
HOLOMicroCloud Hologram Inc
$ 0.588
(26.07%)
135.56M

ATOS Discussion

View Posts
glenn1919 glenn1919 2 weeks ago
ATOS.........................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 weeks ago
ATOS...............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 months ago
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️ 1
Joeyohso Joeyohso 3 months ago
Also no debt and 90m+ in cash. That is unheard of for a research pharma company. They also are extending the employee stock purchase program for all of 2024. This stock is a gem
👍️0
ShadowDiviner72 ShadowDiviner72 3 months ago
New PR, and data release shows that Endoxifen does not only stop the tumor from growing...

It even shows that it eliminates the tumor !!!!!! They cured a patient from breast cancer by taking a simple pill during 6 months!

INCREDIBLE
👍️0
glenn1919 glenn1919 4 months ago
ATOS...........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
Joeyohso Joeyohso 4 months ago
Why the dump today? I was able to grab some at 1.65
💩 1
Monksdream Monksdream 4 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 4 months ago
ATOS new 52 hi
👍️0
Monksdream Monksdream 4 months ago
ATOS 10Q due 4/5
👍️0
Monksdream Monksdream 4 months ago
ATOS new 52 hi
👍️0
glenn1919 glenn1919 4 months ago
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
ATOS..LEVEL 2 LOOKING VERY NICE IN PRE
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
ATOS...GET READY TO RUMBLE...WE ARE LOCKED IN AND LOADED TO 1.73
👍️0
glenn1919 glenn1919 4 months ago
ATOS.............................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
ATOS.........................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 months ago
ATOS..................................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 10 months ago
ATOS................https://stockcharts.com/h-sc/ui?s=ATOS&p=W&b=5&g=0&id=p86431144783
👍️0
Birdbrain Ideas Birdbrain Ideas 11 months ago
There hasn't been a post on this board in six weeks. If these Stage 2 trials turn out well, this board will light up along with the share price.
👍️0
Laster Laster 1 year ago
I loved that wall at $1.04 yesterday. It was calling my name. I was too slow.
Then it was taken out. I wasn’t too upset because….
I was lucky enough for another wall at $1.05 that I helped take out. Then boom.
Chart looked good. News good. Repurchase plan news excellent.
What’s not to like.
Hope to see if move back above $2.
Good luck.
👍️0
tw0122 tw0122 1 year ago
Looking good. Hidden gem not any longer
👍️0
killrEngineer killrEngineer 1 year ago
Wow. No comments?
10 million share repurchase announcement yesterday and study enrollment announcement today.
👍️0
DrJinx DrJinx 2 years ago
This aged like milk. How's that priming for a big run up working out for you? Maybe someday people will realize the company is smoke and mirrors. Keep in mind your CEO is old as F, he dies... this thing tanks even harder.
👍️0
Engle1488 Engle1488 2 years ago
We are primed for a big run up people. In at 1.04
👍️0
Agreed Agreed 2 years ago
The market cap is less than their holdings in cash...clearly undervalued.
👍️0
Agreed Agreed 2 years ago
Insider buying by CEO and CFO, new patent protections...looking promising.
👍️0
DollarSquad DollarSquad 2 years ago
Yes. You likely lost a lot of money. This investment is worthless. RMSL
👍️0
4MVault 4MVault 3 years ago
Did something just happen?
👍️0
slugo1 slugo1 3 years ago
Looking for bottom here
👍️0
ttottip ttottip 3 years ago
Yes, very soon. This will reverse the trend.
👍️0
slugo1 slugo1 3 years ago
Soon
👍️0
ttottip ttottip 3 years ago
Soon the 2.5's , 2.6's .....
👍️0
slugo1 slugo1 3 years ago
Yes
👍️0
ttottip ttottip 3 years ago
The 2.6's on the horizon.
👍️0
slugo1 slugo1 3 years ago
That's one of the things I like about them Also there should be some updates coming
👍️0
ttottip ttottip 3 years ago
140 millions of dollars cash? ATOS can do great things with this money.
👍️0
slugo1 slugo1 3 years ago
Nice buy worth alot when this hits $10.00
👍️0
ttottip ttottip 3 years ago
Almost 36,000 shares buy at 2.49.
👍️0
DrHarleyboy DrHarleyboy 3 years ago
Good Old "Blue Sky Breakout"././//./..//.///.././..////
👍️0
DrHarleyboy DrHarleyboy 3 years ago
The Market is pulling it down with the broad sell-off. Will take some news like VSTM put out today to move up.

👍️0
benchman benchman 3 years ago
Down in pre-market, I guess not many people see it that way :-/
👍️0
DrHarleyboy DrHarleyboy 3 years ago
Atossa Therapeutics Is A Takeover Target Worth Triple It's Current Stock Price

https://seekingalpha.com/instablog/51307855-tradeinvestments2019/5640574-atossa-therapeutics-is-takeover-target-worth-triple-current-stock-price
👍️0
DrHarleyboy DrHarleyboy 3 years ago
Big move coming, lots of buzz this weekend.
👍️0
powerwalker powerwalker 3 years ago
Press Release: Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
BY Dow Jones & Company, Inc.
— 5:22 PM ET 09/07/2021

Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor

Atossa establishes intended criteria for non-use of additional shares for financing transactions

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
) , a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, has adjourned today's special stockholder meeting to 9:00 a.m. Eastern time on October 7, 2021 to allow additional time for stockholders to vote. The Company urges stockholders to vote on the proposal put forth in the proxy statement prior to the new meeting date.

The purpose of the special meeting is to approve an increase in authorized shares of common stock, which requires the affirmative vote of a majority of the shares of common stock issued and outstanding as of the record date. While the votes cast to date have been strongly in favor of the proposal (73% of shares voted have been voted in favor), only 58% of the outstanding shares of common stock have been voted with 42% voting in favor of the proposal. Atossa is therefore adjourning the meeting for 30 days to allow additional time for stockholders to vote.

Leading proxy advisory firms ISS and Glass Lewis have recommended stockholders vote in favor of the proposed increase in authorized shares.

The newly authorized shares of common stock are primarily intended to be used to complete and/or support acquisitions, collaborations, partnerships and licensing transactions. If the proposal is approved by the stockholders, Atossa does not intend to issue any of the newly authorized shares of common stock for the purpose of raising capital in the nine months following approval of the proposal at a price less than $10 per share.

Details of the proposal, the stockholder meeting, and additional information on how to vote your shares can be found in the proxy statement, available here: https://www.sec.gov/Archives/edgar/data/1488039/000143774921019134/atos20210809_ def14a.htm

Atossa stockholders may vote by calling (833) 786-6488 Monday through Friday 9 a.m. to 9 p.m. Eastern Time.

About Atossa Therapeutics ( ATOS
Loading...
Loading...
)

Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.

Forward-Looking Statements Disclaimer Statement

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in breast density, reduction of Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Company Contact:

Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
)

Kyle Guse, CFO and General Counsel

Office: (866) 893-4927

kyle.guse@atossainc.com

Investor Relations Contact:

Core IR

Office:(516) 222-2560

ir@atossainc.com

Source: Atossa Therapeutics, Inc. ( ATOS
Loading...
Loading...
)


Dow Jones Newswires
09-07-21 1722ET
👍️0
slugo1 slugo1 3 years ago
What meeting?
👍️0
DrHarleyboy DrHarleyboy 3 years ago
This could go bigly up, or down after the the meeting!
👍️0
DrHarleyboy DrHarleyboy 3 years ago
October 1st $3.50 calls looking good @ .68 me thinks!
👍️0
XenaLives XenaLives 3 years ago
Still looking for the "missing link" here...
👍️0
eb0783 eb0783 3 years ago
Yeah, mine is not so small.
👍️0
DollarSquad DollarSquad 3 years ago
No
👍️0

Your Recent History

Delayed Upgrade Clock